UnitedHealth Group Looks to Exit Latin America. Is This a Good Move for Investors, or a Sign of More Problems Ahead?

Source Motley_fool

UnitedHealth Group (NYSE: UNH) is in the headlines again, this time, it's to announce that it is exiting Latin America. The announcement is just the latest in a series of news events in what has been a tumultuous year for the once-safe healthcare giant, whose shares are down a staggering 38% year to date as of June 13.

There's been a flurry of bad news surrounding this business, including a change in its CEO last month. Does the company exiting Latin America signal more challenges ahead for the business, and could that affect its long-term growth? Here's what you need to know about this latest development and whether or not you should consider investing in the healthcare stock today.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

A doctor standing in a hospital.

Image source: Getty Images.

UnitedHealth has been losing billions on its Latin American operations

In 2018, UnitedHealth acquired Chilean healthcare company Banmedica in a deal worth $2.8 billion. The deal, however, hasn't paid off for the big health insurer as it has incurred losses totaling more than $8 billion on its Latin American operations since the takeover.

While Latin America may possess some long-term growth potential, it's hard for investors to see much of a benefit from those operations. And without a breakout or mention of its Latin American operations in its most recent quarterly filings, investors may be surprised to know that UnitedHealth even had a presence in that part of the world. Now, it's reportedly looking at a deal worth $1 billion to offload Banmedica and to cut its losses there.

Why this could be a good move for UnitedHealth

UnitedHealth generates more than $400 billion in annual revenue, and while Latin America may have presented an appealing growth opportunity, it was by no means core to its operations. Right now, its focus is on cutting costs and improving its financial position. Getting rid of an unprofitable investment can be a good way to do that. Costs have been rising for UnitedHealth in recent years, and its profit margin is slim at around 5% of revenue.

In previous years, it may have been more tenable to absorb the losses in exchange for future growth opportunities. But as the business has come under pressure and its financials have been falling short of analyst expectations in recent quarters, that may simply no longer be the case.

Back in April, UnitedHealth slashed its guidance for the year, projecting its adjusted per-share earnings to come in between $26 and $26.50, down significantly from its previous forecast of $29.50 to $30. Exiting Latin America isn't going to suddenly fix its problems, but it's potentially a step in the right direction by focusing on cost-cutting measures to improve its financials.

Is UnitedHealth Group stock worth investing in today?

UnitedHealth Group isn't doing well and is now trading around its five-year lows. The stock has tumbled significantly and after the recent resignation of CEO Andrew Witty, it's now Stephen Hemsley who is once again leading the business (he previously served as CEO from 2006 to 2017).

What's encouraging is that the company is still targeting a long-run growth rate of 13% to 16%, suggesting that management believes there is a path to steer the business in the right direction, despite all the adversity it's facing right now.

Currently, shares of UnitedHealth Group trade at around 13 times trailing earnings, which can give investors a fairly good discount; the average S&P 500 stock trades at an earnings multiple of nearly 24. At such a steep reduction, investors are getting a good margin of safety with UnitedHealth Group stock today, and it can make for an attractive long-term buy -- as long as you're willing to be patient with it.

Should you invest $1,000 in UnitedHealth Group right now?

Before you buy stock in UnitedHealth Group, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and UnitedHealth Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $660,821!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $886,880!*

Now, it’s worth noting Stock Advisor’s total average return is 791% — a market-crushing outperformance compared to 174% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of June 9, 2025

David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Bitcoin Must Clear This Critical Cost Basis Level For Continued Upside, Analyst SaysIn a recent CryptoQuant Quicktake post, contributor Crazzyblockk highlighted key Bitcoin (BTC) cost basis zones that the leading cryptocurrency must clear – or avoid breaking below – to
Author  NewsBTC
4 Month 23 Day Wed
In a recent CryptoQuant Quicktake post, contributor Crazzyblockk highlighted key Bitcoin (BTC) cost basis zones that the leading cryptocurrency must clear – or avoid breaking below – to
placeholder
Ethereum ‘Insanely Undervalued’ As Accumulation Addresses Keep Stacking – Is A Rally Imminent?According to a recent X post by crypto trader Coinvo, Ethereum (ETH) is ‘insanely undervalued’ at its current price. Several on-chain metrics appear to support Coinvo’s assessment, as ETH
Author  NewsBTC
5 Month 07 Day Wed
According to a recent X post by crypto trader Coinvo, Ethereum (ETH) is ‘insanely undervalued’ at its current price. Several on-chain metrics appear to support Coinvo’s assessment, as ETH
placeholder
Avalanche Price Forecast: AVAX eyes $30 as FIFA, VanEck back blockchain ecosystemAvalanche (AVAX) is gaining bullish momentum, extending gains on Friday, trading at $25.74 as investor confidence grows on the back of two major developments.
Author  FXStreet
5 Month 23 Day Fri
Avalanche (AVAX) is gaining bullish momentum, extending gains on Friday, trading at $25.74 as investor confidence grows on the back of two major developments.
placeholder
Ethereum Price Tests Ascending Channel Resistance – Breakout Or Breakdown?Ethereum pushed above the $2,820 mark yesterday, strengthening the bullish case for a breakout after weeks of consolidation. The move has created renewed optimism among traders who expect ETH to
Author  NewsBTC
6 Month 12 Day Thu
Ethereum pushed above the $2,820 mark yesterday, strengthening the bullish case for a breakout after weeks of consolidation. The move has created renewed optimism among traders who expect ETH to
placeholder
Ethereum Price Eyes Recovery—Can ETH Kick Off a Fresh Upside Move?Ethereum price started a fresh decline and tested the $2,450 zone. ETH is now correcting losses and might aim for a move above the $2,620 resistance. Ethereum started a fresh decline below the $2,750
Author  NewsBTC
6 Month 16 Day Mon
Ethereum price started a fresh decline and tested the $2,450 zone. ETH is now correcting losses and might aim for a move above the $2,620 resistance. Ethereum started a fresh decline below the $2,750
goTop
quote